Which medications in the drug class PARP Inhibitors are used in the treatment of Ovarian Cancer?

Updated: Aug 10, 2020
  • Author: Andrew E Green, MD; Chief Editor: Yukio Sonoda, MD  more...
  • Print
Answer

PARP Inhibitors

Inhibition of poly (ADP-ribose) polymerase (PARP) enzymes result in disruption of cellular homeostasis and cell death.

Olaparib (Lynparza)

Olaparib is an inhibitor of PARP enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis (eg, DNA transcription, cell cycle regulation, DNA repair). Available as either tablets or capsules. The tablets and capsules are not interchangeable on a mg-to-mg basis due to differences in the dosing and bioavailability of each formulation, and therefore, should not be substituted with one another. The capsules and tablets are indicated as monotherapy for deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer in patients who have been treated with 3 or more prior lines of chemotherapy. Additionally, the tablets are approved for maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. Discontinue bevacizumab before initiating maintenance therapy.

Rucaparib (Rubraca)

By inhibiting PARP, rucaparib may cause increased formation of PARP-DNA complexes, resulting in DNA damage, apoptosis, and cell death. Increased cytotoxicity due to rucaparib was observed in tumor cell lines deficient in BRCA1/2 and other DNA repair genes. Indicated for monotherapy of women with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer who have been treated with ≥2 prior lines of chemotherapy. Also, indicated for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 

Niraparib (Zejula)

Niraparib is a highly selective for PARP-1 and PARP-2. PARP-1 and PARP-2 are involved in detecting DNA damage and promote repair. Inhibiting PARP enzymatic activity results in DNA damage, apoptosis and cell death. PARP inhibitor that is active both in patients with and those without BRCA mutations. Indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Discontinue bevacizumab before initiating maintenance therapy.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!